<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736540</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670AAU05</org_study_id>
    <nct_id>NCT01736540</nct_id>
  </id_info>
  <brief_title>An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)</brief_title>
  <official_title>An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron, one of the most common elements in nature and the most abundant transition metal in the
      body, is readily capable of accepting and donating electrons. This capability makes iron a
      useful component of various, essential biochemical processes. Despite the essential role of
      iron, the excess of iron is toxic to the human body. It is critical for the human body to
      maintain iron balance, since humans have no physiologic mechanism for actively removing iron
      from the body.

      The development of iron overload occurs when iron intake exceeds the body's capacity to
      safely store the iron in the liver, which is the primary store for iron. Long-term
      transfusion therapy, a life-giving treatment for patients with intractable chronic anemia is
      currently the most frequent cause of secondary iron overload.

      The mounting evidence regarding the mortality and morbidity due to chronic iron overload in
      transfusion dependent anaemias has led to the establishment of guidelines that aim the
      improvement of patient outcomes. Further prospective studies are warranted in order to assess
      the impact of iron overload in patients with acquired anaemias.

      In this study, non-invasive R2- and T2*-MRI techniques were applied to the liver and the
      heart, respectively, to complement the primary variable (serum ferritin) assessed in patients
      with various transfusion-dependent anaemias. The main objective of this study was to assess
      the prevalence and severity of cardiac and liver siderosis in patients with transfusional
      siderosis. This study was also aim to establish possible correlations between cardiac and
      liver iron levels with clinical effects in patients with different transfusion-dependent
      anaemias. Patients were eligible for enrollment irrespective of receiving chelation therapy
      or not (and irrespective of the chelating agent used).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to collect information about a large cohort of patients with anaemias
      including MDS, aplastic anemia, Diamond-Blackfan, myeloproliferative disorder, as well as
      haemoglobinopathies (e.g. thalassaemia major, SCD) or other anaemias requiring chronic red
      blood cell transfusions.

      Clinical data was collected retrospectively (if available), unless specified by this protocol
      (e.g. serum ferritin within less than one month prior to enrollment). All assessments
      required for this protocol were performed after the patient informed consent is signed. The
      data was gathered by all study centers and was combined in one central database.

      Data was recorded using an electronic case report form (eCRF) at each study site. Adverse
      events and serious adverse events were recorded for all patients from the date of signed
      patient informed consent until the MRI tests are performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Cardiac and Liver Iron Overload.</measure>
    <time_frame>2 months</time_frame>
    <description>Hepatic iron overload (liver siderosis) and cardiac iron overload (cardiac siderosis) in patients with transfusional siderosis (Myelodysplastic syndrome (MDS), thalassaemia major, non-transfusion-dependent thalassaemia (NTDT) and other anaemias) were measured using MRI (R2 by FerriScan and T2*, respectively).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Siderosis Severity</measure>
    <time_frame>2 months</time_frame>
    <description>Cardiac siderosis severity was measured by MRI (T2*). The severity grade of siderosis was tiered in 3 levels: mild (T2* &gt;= 20ms), moderate (T2* from 10 to 20ms), and severe (T2* &lt;10ms). Mild cardiac siderosis, by the definitions used in this study, were equivalent to not having cardiac siderosis. Values were compared to published thresholds of iron overload to determine severity of transfusion siderosis in the participant population studied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of T2* Levels to Evaluate the Severity of Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</measure>
    <time_frame>2 months</time_frame>
    <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Liver Iron Concentration (LIC) Levels to Evaluate Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</measure>
    <time_frame>2 months</time_frame>
    <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups). The mean data presented are mean estimates of log transformed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Ferritin According to the Presence or Absence of Retrospective Cardiac Events</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Mean serum ferritin according to the presence or absence of cardiac events was assessed for all participant subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Ferritin According to the Presence or Absence of Retrospective Hepatic Events</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Mean serum ferritin according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cardiac T2* According to the Presence or Absence of Retrospective Cardiac Events</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Mean cardiac T2* according to the presence or absence of cardiac events was assessed for all participant subgroups. The mean data presented are mean estimates of log transformed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean LIC According to the Presence or Absence of Retrospective Hepatic Events</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Mean LIC according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Magnetic Susceptibility (BMS)</measure>
    <time_frame>1 month</time_frame>
    <description>Blood samples were collected to assess BMS. The measurement represents absolute magnetic susceptibility at 1 month. Whole blood magnetic susceptibility was calculated by the addition of the dry weight susceptibility and the contribution of the water driven from the sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Transfused With Erythrocytes</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Time Since Most Recent Transfuison of &lt;7 Days, 7 to &lt; 14 Days, 14 to &lt; 30 Days, 30 to &lt; 60 Days or &gt;= 60 Days</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Erythrocyte Units Transfused in Last 12 Months</measure>
    <time_frame>12 months - retrospective</time_frame>
    <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Quality of Life (QOL) Scores</measure>
    <time_frame>1 month</time_frame>
    <description>Quality of life was assessed using the Short Form 36 (SF-36) Health Survey. The SF-36 consists of 8 sub-scales: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. The raw sores of the 8 scales are transformed to a 0 - 100 scale where 0 indicates maximum disability and 100 indicates no disability. There also are two physical and mental health summary measures. Each summary measure is the mean average of the 4 associated sub-scale scores. The range for each summary measure is 0 to 100 where 0 represents maximum disability and 100 represents no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Low Medium or High Adherence to Iron Chelator Therapy</measure>
    <time_frame>1 month</time_frame>
    <description>Adherence of participants was assessed using an adherence questionnaire. Adherence questionnaires were completed only by participants who received chelating agents. Participants answered yes or no to 6 statements such as &quot;Forgot to take pills&quot;. Based on the responses to these questions, adherence was classified as low, medium or high.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Treatment Decisions Based on MRI Results</measure>
    <time_frame>2 months</time_frame>
    <description>Treatment decisions were recorded after the investigator evaluated the MRI results, in order to assess the impact of such diagnostic test on the overall clinical management of participants with iron overload. Investigators answered the following question: &quot;Since the MRI scan, have you changed or are planning to change the management of iron in your subject?&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia</condition>
  <arm_group>
    <arm_group_label>Magnetic Resonance Imaging (MRI)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).</description>
    <arm_group_label>Magnetic Resonance Imaging (MRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Confirmed clinical diagnosis of one of the following disease states: 1.
             Myelodysplastic syndromes, 2. Thalassaemia major, 3.Other anaemias (e.g. NTDT, SCD,
             Diamond-Blackfan anaemia, aplastic anaemia, myeloproliferative disease)

          -  Lifetime history of at least 20 units of red blood cell transfusions AND serum
             ferritin level &gt; 500 ng/ml; patients with NTDT are not required to have a minimum of
             20 units of red blood cell transfusions, but must have serum ferritin level &gt; 300
             ng/ml (serum ferritin for all patients must be measured up to 1 month prior to
             enrollment)

          -  Written informed consent obtained prior to any procedure required by this protocol

        Exclusion Criteria:

        Any condition that does not allow the MRI test to be performed: 1. Cardiac pacemaker, 2.
        Ferromagnetic metal implants other than those approved as safe for use in MR scanners
        (Example: some types of aneurysm clips, shrapnel), 3. Obesity (exceeding the equipment
        limits), 4. Patients who are claustrophobic to MR Women who are pregnant Unwillingness or
        being unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <results_first_submitted>May 28, 2016</results_first_submitted>
  <results_first_submitted_qc>July 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2016</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iron overload, liver iron concentration (LIC), cardiac siderosis, transfusional siderosis, magnetic resonance imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Siderosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Magnetic Resonance Imaging (MRI)</title>
          <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not complete scan within 45 days</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to tolerate MRI; claustrophobic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No show for MRI appointment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to make MRI appointment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnetic Resonance Imaging (MRI)</title>
          <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="20.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cardiac and Liver Iron Overload.</title>
        <description>Hepatic iron overload (liver siderosis) and cardiac iron overload (cardiac siderosis) in patients with transfusional siderosis (Myelodysplastic syndrome (MDS), thalassaemia major, non-transfusion-dependent thalassaemia (NTDT) and other anaemias) were measured using MRI (R2 by FerriScan and T2*, respectively).</description>
        <time_frame>2 months</time_frame>
        <population>Only participants with valid T2* by MRI and valid liver iron concentration (LIC) by MRI were included for the cardiac siderosis and liver siderosis analyses, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiac and Liver Iron Overload.</title>
          <description>Hepatic iron overload (liver siderosis) and cardiac iron overload (cardiac siderosis) in patients with transfusional siderosis (Myelodysplastic syndrome (MDS), thalassaemia major, non-transfusion-dependent thalassaemia (NTDT) and other anaemias) were measured using MRI (R2 by FerriScan and T2*, respectively).</description>
          <population>Only participants with valid T2* by MRI and valid liver iron concentration (LIC) by MRI were included for the cardiac siderosis and liver siderosis analyses, respectively.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Siderosis Severity</title>
        <description>Cardiac siderosis severity was measured by MRI (T2*). The severity grade of siderosis was tiered in 3 levels: mild (T2* &gt;= 20ms), moderate (T2* from 10 to 20ms), and severe (T2* &lt;10ms). Mild cardiac siderosis, by the definitions used in this study, were equivalent to not having cardiac siderosis. Values were compared to published thresholds of iron overload to determine severity of transfusion siderosis in the participant population studied.</description>
        <time_frame>2 months</time_frame>
        <population>Only participants with valid T2* by MRI were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Siderosis Severity</title>
          <description>Cardiac siderosis severity was measured by MRI (T2*). The severity grade of siderosis was tiered in 3 levels: mild (T2* &gt;= 20ms), moderate (T2* from 10 to 20ms), and severe (T2* &lt;10ms). Mild cardiac siderosis, by the definitions used in this study, were equivalent to not having cardiac siderosis. Values were compared to published thresholds of iron overload to determine severity of transfusion siderosis in the participant population studied.</description>
          <population>Only participants with valid T2* by MRI were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                    <measurement group_id="O2" value="77.6"/>
                    <measurement group_id="O3" value="95.7"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="10.5"/>
                    <measurement group_id="O3" value="4.3"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of T2* Levels to Evaluate the Severity of Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</title>
        <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups).</description>
        <time_frame>2 months</time_frame>
        <population>Only participants with valid T2* by MRI were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of T2* Levels to Evaluate the Severity of Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</title>
          <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups).</description>
          <population>Only participants with valid T2* by MRI were included in the analysis.</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall (n=228,76,69,18,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="27.62" upper_limit="32.62"/>
                    <measurement group_id="O2" value="23.95" lower_limit="21.46" upper_limit="26.72"/>
                    <measurement group_id="O3" value="30.13" lower_limit="26.78" upper_limit="33.90"/>
                    <measurement group_id="O4" value="32.69" lower_limit="25.94" upper_limit="41.19"/>
                    <measurement group_id="O5" value="30.76" lower_limit="27.29" upper_limit="34.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chelation naïve/minimally exposed(n=75,0,27,11,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.55" lower_limit="28.71" upper_limit="36.91"/>
                    <measurement group_id="O2" value="NA">No participants were minimally exposed to chelator treatment.</measurement>
                    <measurement group_id="O3" value="32.05" lower_limit="26.66" upper_limit="38.53"/>
                    <measurement group_id="O4" value="32.95" lower_limit="24.70" upper_limit="43.97"/>
                    <measurement group_id="O5" value="32.66" lower_limit="27.91" upper_limit="38.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chelator exposed (n=153,76,42,7,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.25" lower_limit="25.28" upper_limit="31.57"/>
                    <measurement group_id="O2" value="23.95" lower_limit="21.46" upper_limit="26.72"/>
                    <measurement group_id="O3" value="28.32" lower_limit="24.43" upper_limit="32.82"/>
                    <measurement group_id="O4" value="32.43" lower_limit="22.59" upper_limit="46.55"/>
                    <measurement group_id="O5" value="28.96" lower_limit="24.17" upper_limit="34.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Liver Iron Concentration (LIC) Levels to Evaluate Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</title>
        <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups). The mean data presented are mean estimates of log transformed data.</description>
        <time_frame>2 months</time_frame>
        <population>Only participants with valid LIC by MRI were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Liver Iron Concentration (LIC) Levels to Evaluate Iron Overload Due to Transfusion Therapy in Chelation-naïve and Chelation-treated Participant Subgroups</title>
          <description>Iron overload due to transfusion therapy was assessed based on chelation status of each participant (i.e. minimally exposed to chelator treatment and chelation-treated patient subgroups). The mean data presented are mean estimates of log transformed data.</description>
          <population>Only participants with valid LIC by MRI were included in the analysis.</population>
          <units>mg Fe/g</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall (n=228,76,69,18,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" lower_limit="9.42" upper_limit="13.17"/>
                    <measurement group_id="O2" value="8.09" lower_limit="5.62" upper_limit="10.57"/>
                    <measurement group_id="O3" value="10.84" lower_limit="8.18" upper_limit="13.50"/>
                    <measurement group_id="O4" value="12.38" lower_limit="7.16" upper_limit="17.59"/>
                    <measurement group_id="O5" value="12.28" lower_limit="9.58" upper_limit="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chelation naïve/minimally exposed(n=75,0,27,11,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" lower_limit="5.90" upper_limit="11.56"/>
                    <measurement group_id="O2" value="NA">No participants were minimally exposed.</measurement>
                    <measurement group_id="O3" value="10.28" lower_limit="6.13" upper_limit="14.43"/>
                    <measurement group_id="O4" value="5.00" lower_limit="-1.50" upper_limit="11.50"/>
                    <measurement group_id="O5" value="10.92" lower_limit="7.37" upper_limit="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chelator exposed (n=153,76,42,7,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.22" lower_limit="10.72" upper_limit="15.72"/>
                    <measurement group_id="O2" value="8.09" lower_limit="5.62" upper_limit="10.57"/>
                    <measurement group_id="O3" value="11.40" lower_limit="8.07" upper_limit="14.72"/>
                    <measurement group_id="O4" value="19.76" lower_limit="11.60" upper_limit="27.91"/>
                    <measurement group_id="O5" value="13.64" lower_limit="9.56" upper_limit="17.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Ferritin According to the Presence or Absence of Retrospective Cardiac Events</title>
        <description>Mean serum ferritin according to the presence or absence of cardiac events was assessed for all participant subgroups.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with serum ferritin values and previous cardiac events data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Ferritin According to the Presence or Absence of Retrospective Cardiac Events</title>
          <description>Mean serum ferritin according to the presence or absence of cardiac events was assessed for all participant subgroups.</description>
          <population>Participants with serum ferritin values and previous cardiac events data were included in the analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac event in past 12 months = yes (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153.6" spread="1878.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac event in past 12 months = no (n=226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2150.2" spread="1914.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Ferritin According to the Presence or Absence of Retrospective Hepatic Events</title>
        <description>Mean serum ferritin according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with serum ferritin values and previous hepatic events data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Ferritin According to the Presence or Absence of Retrospective Hepatic Events</title>
          <description>Mean serum ferritin according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
          <population>Participants with serum ferritin values and previous hepatic events data were included in the analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepatic event in the past 12 months = yes (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3302.8" spread="2684.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic event in the past 12 months = no (n=231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2124.1" spread="1879.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cardiac T2* According to the Presence or Absence of Retrospective Cardiac Events</title>
        <description>Mean cardiac T2* according to the presence or absence of cardiac events was assessed for all participant subgroups. The mean data presented are mean estimates of log transformed data.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with valid T2* by MRI results were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cardiac T2* According to the Presence or Absence of Retrospective Cardiac Events</title>
          <description>Mean cardiac T2* according to the presence or absence of cardiac events was assessed for all participant subgroups. The mean data presented are mean estimates of log transformed data.</description>
          <population>Participants with valid T2* by MRI results were included in the analysis.</population>
          <units>log10 (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac event in past 12 months = yes (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.0979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac event in the past 12 months = no (n=226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.445" spread="0.2188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean LIC According to the Presence or Absence of Retrospective Hepatic Events</title>
        <description>Mean LIC according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with LIC by MRI were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean LIC According to the Presence or Absence of Retrospective Hepatic Events</title>
          <description>Mean LIC according to the presence or absence of hepatic events was assessed for all participant subgroups.</description>
          <population>Participants with LIC by MRI were included in the analysis.</population>
          <units>mg Fe/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepatic event in past 12 months = yes (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.51" spread="15.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic event in past 12 months = no (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.08" spread="10.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Magnetic Susceptibility (BMS)</title>
        <description>Blood samples were collected to assess BMS. The measurement represents absolute magnetic susceptibility at 1 month. Whole blood magnetic susceptibility was calculated by the addition of the dry weight susceptibility and the contribution of the water driven from the sample.</description>
        <time_frame>1 month</time_frame>
        <population>Participants with BMS values were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Magnetic Susceptibility (BMS)</title>
          <description>Blood samples were collected to assess BMS. The measurement represents absolute magnetic susceptibility at 1 month. Whole blood magnetic susceptibility was calculated by the addition of the dry weight susceptibility and the contribution of the water driven from the sample.</description>
          <population>Participants with BMS values were analyzed.</population>
          <units>emu/g wet wt/Oe</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Transfused With Erythrocytes</title>
        <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with a erythrocyte transfusion history were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Transfused With Erythrocytes</title>
          <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
          <population>Participants with a erythrocyte transfusion history were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="36.8"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Time Since Most Recent Transfuison of &lt;7 Days, 7 to &lt; 14 Days, 14 to &lt; 30 Days, 30 to &lt; 60 Days or &gt;= 60 Days</title>
        <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with data on time since their most recent transfusion were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Time Since Most Recent Transfuison of &lt;7 Days, 7 to &lt; 14 Days, 14 to &lt; 30 Days, 30 to &lt; 60 Days or &gt;= 60 Days</title>
          <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
          <population>Participants with data on time since their most recent transfusion were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="72.8"/>
                    <measurement group_id="O3" value="31.0"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - &lt; 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="28.2"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 - &lt; 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 - &lt; 60 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="9.9"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="16.9"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Erythrocyte Units Transfused in Last 12 Months</title>
        <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
        <time_frame>12 months - retrospective</time_frame>
        <population>Participants with 'number of units transfused' data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Erythrocyte Units Transfused in Last 12 Months</title>
          <description>Transfusion requirement in participants with acquired anaemias with history of receiving chelation therapy was assessed.</description>
          <population>Participants with 'number of units transfused' data were included in the analysis.</population>
          <units>number of units transfused</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="21.0"/>
                    <measurement group_id="O2" value="41.4" spread="9.5"/>
                    <measurement group_id="O3" value="34.7" spread="25.6"/>
                    <measurement group_id="O4" value="8.4" spread="12.2"/>
                    <measurement group_id="O5" value="24.8" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Quality of Life (QOL) Scores</title>
        <description>Quality of life was assessed using the Short Form 36 (SF-36) Health Survey. The SF-36 consists of 8 sub-scales: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. The raw sores of the 8 scales are transformed to a 0 - 100 scale where 0 indicates maximum disability and 100 indicates no disability. There also are two physical and mental health summary measures. Each summary measure is the mean average of the 4 associated sub-scale scores. The range for each summary measure is 0 to 100 where 0 represents maximum disability and 100 represents no disability.</description>
        <time_frame>1 month</time_frame>
        <population>Only participants with data for each subscale were included in the analysis for that subscale.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Quality of Life (QOL) Scores</title>
          <description>Quality of life was assessed using the Short Form 36 (SF-36) Health Survey. The SF-36 consists of 8 sub-scales: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. The raw sores of the 8 scales are transformed to a 0 - 100 scale where 0 indicates maximum disability and 100 indicates no disability. There also are two physical and mental health summary measures. Each summary measure is the mean average of the 4 associated sub-scale scores. The range for each summary measure is 0 to 100 where 0 represents maximum disability and 100 represents no disability.</description>
          <population>Only participants with data for each subscale were included in the analysis for that subscale.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.10" spread="11.471"/>
                    <measurement group_id="O2" value="49.79" spread="9.144"/>
                    <measurement group_id="O3" value="35.67" spread="9.791"/>
                    <measurement group_id="O4" value="49.37" spread="7.576"/>
                    <measurement group_id="O5" value="41.56" spread="11.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.54" spread="10.895"/>
                    <measurement group_id="O2" value="49.51" spread="8.836"/>
                    <measurement group_id="O3" value="36.71" spread="9.462"/>
                    <measurement group_id="O4" value="46.46" spread="8.717"/>
                    <measurement group_id="O5" value="39.44" spread="10.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.41" spread="10.969"/>
                    <measurement group_id="O2" value="50.48" spread="11.084"/>
                    <measurement group_id="O3" value="45.52" spread="10.750"/>
                    <measurement group_id="O4" value="54.66" spread="7.773"/>
                    <measurement group_id="O5" value="47.60" spread="10.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.65" spread="9.909"/>
                    <measurement group_id="O2" value="44.82" spread="9.365"/>
                    <measurement group_id="O3" value="39.48" spread="9.595"/>
                    <measurement group_id="O4" value="43.23" spread="8.893"/>
                    <measurement group_id="O5" value="39.80" spread="10.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.59" spread="10.267"/>
                    <measurement group_id="O2" value="50.18" spread="9.277"/>
                    <measurement group_id="O3" value="42.41" spread="9.190"/>
                    <measurement group_id="O4" value="48.95" spread="8.424"/>
                    <measurement group_id="O5" value="42.67" spread="10.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.99" spread="11.075"/>
                    <measurement group_id="O2" value="48.98" spread="9.869"/>
                    <measurement group_id="O3" value="42.37" spread="10.486"/>
                    <measurement group_id="O4" value="46.43" spread="9.905"/>
                    <measurement group_id="O5" value="42.67" spread="12.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.83" spread="12.977"/>
                    <measurement group_id="O2" value="48.99" spread="11.236"/>
                    <measurement group_id="O3" value="40.11" spread="13.101"/>
                    <measurement group_id="O4" value="47.03" spread="10.552"/>
                    <measurement group_id="O5" value="40.89" spread="13.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.84" spread="11.149"/>
                    <measurement group_id="O2" value="50.09" spread="11.240"/>
                    <measurement group_id="O3" value="46.69" spread="9.495"/>
                    <measurement group_id="O4" value="48.74" spread="9.846"/>
                    <measurement group_id="O5" value="46.12" spread="12.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.48" spread="9.808"/>
                    <measurement group_id="O2" value="48.75" spread="7.809"/>
                    <measurement group_id="O3" value="37.55" spread="8.748"/>
                    <measurement group_id="O4" value="50.34" spread="6.392"/>
                    <measurement group_id="O5" value="41.93" spread="9.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.76" spread="11.622"/>
                    <measurement group_id="O2" value="49.58" spread="10.354"/>
                    <measurement group_id="O3" value="45.91" spread="10.349"/>
                    <measurement group_id="O4" value="47.47" spread="10.832"/>
                    <measurement group_id="O5" value="44.08" spread="13.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Low Medium or High Adherence to Iron Chelator Therapy</title>
        <description>Adherence of participants was assessed using an adherence questionnaire. Adherence questionnaires were completed only by participants who received chelating agents. Participants answered yes or no to 6 statements such as &quot;Forgot to take pills&quot;. Based on the responses to these questions, adherence was classified as low, medium or high.</description>
        <time_frame>1 month</time_frame>
        <population>Participants who were on iron chelator therapy at screening, and had answered at least one question on the questionnaire and had sufficient information to score the questionnaire, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
          <group group_id="O2">
            <title>Thalassemia Major</title>
            <description>Subset of overall participants with thalassemia major</description>
          </group>
          <group group_id="O3">
            <title>Melodysplastic Syndrome (MDS)</title>
            <description>Subset of overall participants with MDS</description>
          </group>
          <group group_id="O4">
            <title>Non-transfusion-dependent Anaemia (NTDT)</title>
            <description>Subset of overall participants with NTDT</description>
          </group>
          <group group_id="O5">
            <title>Other Anaemias</title>
            <description>Subset of overall participants with other types of anaemia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Low Medium or High Adherence to Iron Chelator Therapy</title>
          <description>Adherence of participants was assessed using an adherence questionnaire. Adherence questionnaires were completed only by participants who received chelating agents. Participants answered yes or no to 6 statements such as &quot;Forgot to take pills&quot;. Based on the responses to these questions, adherence was classified as low, medium or high.</description>
          <population>Participants who were on iron chelator therapy at screening, and had answered at least one question on the questionnaire and had sufficient information to score the questionnaire, were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="11.8"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="73.5"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Treatment Decisions Based on MRI Results</title>
        <description>Treatment decisions were recorded after the investigator evaluated the MRI results, in order to assess the impact of such diagnostic test on the overall clinical management of participants with iron overload. Investigators answered the following question: &quot;Since the MRI scan, have you changed or are planning to change the management of iron in your subject?&quot;.</description>
        <time_frame>2 months</time_frame>
        <population>Participants, for whom treatment decision questionnaire results were provided and for whom MRI results were available, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Resonance Imaging (MRI)</title>
            <description>All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Treatment Decisions Based on MRI Results</title>
          <description>Treatment decisions were recorded after the investigator evaluated the MRI results, in order to assess the impact of such diagnostic test on the overall clinical management of participants with iron overload. Investigators answered the following question: &quot;Since the MRI scan, have you changed or are planning to change the management of iron in your subject?&quot;.</description>
          <population>Participants, for whom treatment decision questionnaire results were provided and for whom MRI results were available, were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Answer = yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Answer = no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thalassaemia Major</title>
          <description>Subset of overall participants with thalassemia major</description>
        </group>
        <group group_id="E2">
          <title>Myelodysplastic Syndrome (MDS)</title>
          <description>Subset of overall participants with MDS</description>
        </group>
        <group group_id="E3">
          <title>Other Anaemia</title>
          <description>Subset of overall participants with other types of anaemias</description>
        </group>
        <group group_id="E4">
          <title>Non-transfusion-dependent Anaemia (NTDT)</title>
          <description>Subset of overall participants with NTDT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Medical device site erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Medical device site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

